

# Haiyan Yang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9654670/publications.pdf>

Version: 2024-02-01

9  
papers

141  
citations

1684188  
5  
h-index

1588992  
8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

30  
citing authors

#	ARTICLE	IF	CITATIONS
1	High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma. <i>BMC Cancer</i> , 2022, 22, 9.	2.6	7
2	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. <i>Blood</i> , 2022, 139, 3148-3158.	1.4	43
3	Altered pathways and targeted therapy in double hit lymphoma. <i>Journal of Hematology and Oncology</i> , 2022, 15, 26.	17.0	13
4	Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells. <i>European Journal of Medicinal Chemistry</i> , 2022, 235, 114257.	5.5	4
5	Isocitrate Dehydrogenase 2 Inhibitors for the Treatment of Hematologic Malignancies: Advances and Future Opportunities. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1113-1122.	2.4	0
6	Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma—evaluation of anti-tumor efficacy and brain distribution. <i>Translational Cancer Research</i> , 2021, 10, 1975-1983.	1.0	13
7	Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China. <i>Journal of Hematology and Oncology</i> , 2021, 14, 131.	17.0	9
8	Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. <i>Cancer Medicine</i> , 2021, 10, 999-1011.	2.8	50
9	Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. <i>Blood</i> , 2020, 136, 39-40.	1.4	2